Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018 Feb 7. doi: 10.1159/000486286. [Epub ahead of print]

PMID:
29414827
2.

Convergent microevolution of Cryptococcus neoformans hypervirulence in the laboratory and the clinic.

Arras SDM, Ormerod KL, Erpf PE, Espinosa MI, Carpenter AC, Blundell RD, Stowasser SR, Schulz BL, Tanurdzic M, Fraser JA.

Sci Rep. 2017 Dec 20;7(1):17918. doi: 10.1038/s41598-017-18106-2.

3.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2017 Oct 9. pii: thoraxjnl-2016-209701. doi: 10.1136/thoraxjnl-2016-209701. [Epub ahead of print]

4.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

PMID:
28889759
5.

Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.

Costabel U, Stansen W, Stowasser S.

Am J Respir Crit Care Med. 2017 May 1;195(9):1275. doi: 10.1164/rccm.201610-2155LE. No abstract available.

PMID:
28459331
6.

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.

Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM.

Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26.

7.

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.

Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G.

Lung. 2016 Oct;194(5):739-43. doi: 10.1007/s00408-016-9912-1. Epub 2016 Jul 4.

8.

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.

Raghu G, Wells AU, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM.

Am J Respir Crit Care Med. 2017 Jan 1;195(1):78-85. doi: 10.1164/rccm.201602-0402OC.

9.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, Schlenker-Herceg R, Stowasser S, Brown KK.

Respir Med. 2016 Apr;113:74-9. doi: 10.1016/j.rmed.2016.02.001. Epub 2016 Feb 3.

10.

New guideline for idiopathic pulmonary fibrosis.

Stowasser S, Hallmann C.

Lancet. 2015 Nov 7;386(10006):1823-4. doi: 10.1016/S0140-6736(15)00765-5. No abstract available.

PMID:
26843309
11.

Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel.

Morell F, Esser D, Lim J, Stowasser S, Villacampa A, Nieves D, Brosa M.

BMC Pulm Med. 2016 Jan 12;16:7. doi: 10.1186/s12890-016-0168-6.

12.

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.

Bonella F, Stowasser S, Wollin L.

Drug Des Devel Ther. 2015 Dec 14;9:6407-19. doi: 10.2147/DDDT.S76648. eCollection 2015. Review.

13.

Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.

Raghu G, Amatto VC, Behr J, Stowasser S.

Eur Respir J. 2015 Oct;46(4):1113-30. doi: 10.1183/13993003.02316-2014. Review.

14.

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A.

Am J Respir Crit Care Med. 2016 Jan 15;193(2):178-85. doi: 10.1164/rccm.201503-0562OC.

PMID:
26393389
15.

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M.

Eur Respir J. 2015 May;45(5):1434-45. doi: 10.1183/09031936.00174914. Epub 2015 Mar 5. Review.

16.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

17.

Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.

Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR.

Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.

18.

Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial.

Beeh KM, Glaab T, Stowasser S, Schmidt H, Fabbri LM, Rabe KF, Vogelmeier CF.

Respir Res. 2013 Oct 29;14:116. doi: 10.1186/1465-9921-14-116.

Supplemental Content

Loading ...
Support Center